Logo image of PLSE

PULSE BIOSCIENCES INC (PLSE) Stock Fundamental Analysis

NASDAQ:PLSE - Nasdaq - US74587B1017 - Common Stock - Currency: USD

16.79  +1.69 (+11.19%)

After market: 16.79 0 (0%)

Fundamental Rating

2

PLSE gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 187 industry peers in the Health Care Equipment & Supplies industry. No worries on liquidiy or solvency for PLSE as it has an excellent financial health rating, but there are worries on the profitability. PLSE has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

PLSE had negative earnings in the past year.
PLSE had a negative operating cash flow in the past year.
In the past 5 years PLSE always reported negative net income.
PLSE had a negative operating cash flow in each of the past 5 years.
PLSE Yearly Net Income VS EBIT VS OCF VS FCFPLSE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

PLSE has a Return On Assets of -45.17%. This is in the lower half of the industry: PLSE underperforms 66.31% of its industry peers.
With a Return On Equity value of -50.86%, PLSE perfoms like the industry average, outperforming 47.59% of the companies in the same industry.
Industry RankSector Rank
ROA -45.17%
ROE -50.86%
ROIC N/A
ROA(3y)-62.31%
ROA(5y)-85%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PLSE Yearly ROA, ROE, ROICPLSE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K 2K 2.5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PLSE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PLSE Yearly Profit, Operating, Gross MarginsPLSE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2K -4K -6K -8K

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for PLSE has been increased compared to 1 year ago.
PLSE has more shares outstanding than it did 5 years ago.
PLSE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PLSE Yearly Shares OutstandingPLSE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
PLSE Yearly Total Debt VS Total AssetsPLSE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

PLSE has an Altman-Z score of 40.57. This indicates that PLSE is financially healthy and has little risk of bankruptcy at the moment.
PLSE's Altman-Z score of 40.57 is amongst the best of the industry. PLSE outperforms 98.93% of its industry peers.
There is no outstanding debt for PLSE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 40.57
ROIC/WACCN/A
WACCN/A
PLSE Yearly LT Debt VS Equity VS FCFPLSE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 15.58 indicates that PLSE has no problem at all paying its short term obligations.
PLSE's Current ratio of 15.58 is amongst the best of the industry. PLSE outperforms 97.86% of its industry peers.
A Quick Ratio of 15.58 indicates that PLSE has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 15.58, PLSE belongs to the top of the industry, outperforming 98.40% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 15.58
Quick Ratio 15.58
PLSE Yearly Current Assets VS Current LiabilitesPLSE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 55.68% over the past year.
The Revenue for PLSE has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)55.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, PLSE will show a very negative growth in Earnings Per Share. The EPS will decrease by -17.48% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-17.69%
EPS Next 2Y-18.84%
EPS Next 3Y-17.48%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PLSE Yearly Revenue VS EstimatesPLSE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2025 2026 2M 4M 6M 8M 10M
PLSE Yearly EPS VS EstimatesPLSE Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

PLSE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PLSE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PLSE Price Earnings VS Forward Price EarningsPLSE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PLSE Per share dataPLSE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 1.5

4.3 Compensation for Growth

PLSE's earnings are expected to decrease with -17.48% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-18.84%
EPS Next 3Y-17.48%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PLSE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PULSE BIOSCIENCES INC

NASDAQ:PLSE (8/13/2025, 8:00:00 PM)

After market: 16.79 0 (0%)

16.79

+1.69 (+11.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-12 2025-08-12/amc
Earnings (Next)10-28 2025-10-28
Inst Owners8.65%
Inst Owner Change0.12%
Ins Owners72.66%
Ins Owner Change-0.06%
Market Cap1.13B
Analysts85.71
Price Target22.44 (33.65%)
Short Float %13.92%
Short Ratio14.34
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)450%
PT rev (3m)450%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 9.54
P/tB 9.86
EV/EBITDA N/A
EPS(TTM)-0.7
EYN/A
EPS(NY)-1.1
Fwd EYN/A
FCF(TTM)-0.6
FCFYN/A
OCF(TTM)-0.6
OCFYN/A
SpS0
BVpS1.76
TBVpS1.7
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -45.17%
ROE -50.86%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-62.31%
ROA(5y)-85%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 14.2%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.58
Quick Ratio 15.58
Altman-Z 40.57
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)16.68%
Cap/Depr(5y)25.66%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)55.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y-17.69%
EPS Next 2Y-18.84%
EPS Next 3Y-17.48%
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-41.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-5.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-5.51%
OCF growth 3YN/A
OCF growth 5YN/A